Epigral Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/n7slz3f1hk5tc4pwh5fjvjt6.pdf

Key Takeaways


CPVC: The Margin Reset

Kotecha: "Q3 was impacted because of the high cost of inventory and also the realizations for the product has cooled off. So considering that, we believe that Q3 was impacted in that manner. But Q4 onwards, we believe that the margin will be uptick."

Chlorotoluene Value Chain: The Next Growth Leg


ECH & Caustic Soda: Structural Shifts

Patel: "The Trump is not supporting the biodiesel project and the glycerin is a byproduct of biodiesel, so the glycerin price is going to remain high till the biodiesel are not getting supported by the global leaders."

Capex Pipeline & Capacity Expansion

Kotecha: "Maybe for initial 6 months or a year's time, we have to run our plant at lower utilizations. But eventually... we tend to believe that in maybe a matter of 1 or 2 years, we should be able to run our plant at optimum utilization levels even after considering the new capacities which are coming because growth in India is there."

Demand Environment & Pricing

Patel: "China has announced 250 products, they have withdrawn the rebate of the product. So I think globally and other petrochemical products are also going up. So all commodity prices are going up."

Financials in Brief


Guidance & Commitments

CommitmentSpecificsTimeline
CPVC margin recoveryMargins to uptick from Q4 as lower-cost inventory replaces high-cost stock and realizations improveQ4 FY26 onwards
Chlorotoluene revenue contributionSizable P&L contribution; long-term contracts to formQ1 FY27 onwards
CPVC/ECH capacity commissioningDoubling projects on track within announced timeline and budgetExpected September 2026
Post-expansion utilization rampRun at lower utilization for initial 6-12 months, reach optimum in 1-2 yearsFY27-FY29
New capex/chemistry announcementDetails of new projects and new chemistry to be disclosedBy end of FY26 / coming months
Next-wave project contributionNew initiatives to drive significant growthFY29 onwards
Volume growthGood volume growth expectedFY27

Key Metrics

MetricQ3 FY26
Revenue₹603 cr, +2% QoQ
EBITDA₹103 cr, -22% QoQ
EBITDA margin17%, contracted from prior quarter; 9-month FY26 margin at 22%
PAT₹39 cr, vs ₹51 cr in prior quarter; includes one-time labor code expense
9-month FY26 revenue₹1,807 cr, -7% YoY
9-month FY26 EBITDA₹398 cr, margin at 22% vs 28% in corresponding period
Derivatives & specialty revenue share52%, up from 50% QoQ
Overall plant utilization78%, flat QoQ; 81% in Q3 FY25
9-month FY26 plant utilization76%, vs 82% in corresponding period
ROCE17% as on 31 Dec 2025; 20% excluding capital work in progress
Net debt₹557 cr, vs ₹531 cr as on 31 Dec 2024
Net debt to EBITDA1x, vs 0.8x as on 31 Dec 2024
Capex spent during FY26₹337 cr
ECU₹29,000–30,000, marginally down ₹500–1,000 QoQ
CPVC realization₹95–100 per kg
ECH realization₹165–170 per kg
Chlorine integration70–75%
CPVC demand (India)~280,000 tonnes expected by 31 Mar 2026, growing 10–12% annually